Human Papilloma Virus (HPV)
1
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 3 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Daré BioscienceCA - San Diego
1 program1
Lopinavir / ritonavirPhase 2Small Molecule1 trial
Active Trials
Colorado TherapeuticsCO - Louisville
1 programReminder/recall notices for vaccinesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Daré BioscienceLopinavir / ritonavir
Genentechcobas® 4800 HPV Test
Colorado TherapeuticsReminder/recall notices for vaccines
Clinical Trials (3)
Total enrollment: 52,133 patients across 3 trials
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
Start: Jun 2026Est. completion: Dec 2027118 patients
Phase 2Not Yet Recruiting
Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease
Start: May 2008Est. completion: Jun 201347,208 patients
N/ACompleted
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
Start: Oct 2007Est. completion: Sep 20104,807 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.